Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles.

The global Papaverine Hydrochloride Injection market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Papaverine Hydrochloride Injection volume and value at global level, regional level and company level. From a global perspective, this report represents overall Papaverine Hydrochloride Injection market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Sandoz
American Regent
Jiangsu Hengrui Medicine
Chengdu Brilliant Pharmaceutical Group
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
30 mg/mL
120 mg/10 mL

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies